SCHEMBL1825014

SCHEMBL1825014

C[C@]1(OC(=O)c2ccccc2)[C@H](OO)O[C@H](COC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
POLB P06746 2/20 0.42
GAA P10253 2/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 1/20 0.41
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
MAPT P10636 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HPGD P15428 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA5 P30532 1/20 0.36
CHRNA7 P36544 1/20 0.36
CHRNA4 P43681 1/20 0.36
LMNA P02545 1/20 0.36
CES2 O00748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13941468 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL13857762 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL14571165 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL19276651 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL14853799 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL882168 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL721635 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL21418908 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL21418911 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1
SCHEMBL14037391 0.93 ALDH1A1 (0.49) ALDH1A1POLBGAAMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2319853-B1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS INC (US) 2014-03-12 EP disclosed
EP-2319853-A1 Process for the production of 2'-branched nucleosides Idenix (Cayman) Limited (KY) 2011-05-11 EP disclosed
US-7598373-B2 Process for the production of 2-C-methyl-D-ribonolactone IDENIX PHARMACEUTICALS, INC. (US) 2009-10-06 US disclosed
US-20050020825-A1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS LLC 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020825-A1 Process for the production of 2'-branched nucleosides RNGTT, MTAP, NSUN2 ALDH1A1 2027/4885POLB 68/4885GAA 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.